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Table 1. Commercially available HCV RNA detection assays
Assay Manufacturer Method
Detection limit or 
dynamic range (IU/mL)
Qualitative HCV RNA dection assays
  Amplicor™ HCV 2.0 Roche Molecular System Manual RT-PCR 50
  Cobas Amplicor™ HCV 2.0 Roche Molecular System Semi-automated RT-PCR 50
  Versant™ HCV Siemens Health Care Diagnostics Semi-automated TMA 10
Quantitative HCV RNA detection assays
  Amplicor™ HCV Monitor Roche Molecular System Manual RT-PCR 600-500,000
  Cobas Amplicor™ HCV Monitor 2.0 Roche Molecular System Semi-automated RT-PCR 600-500,000
  HCV SuperQuant™ National Genetics Institute Semi-automated RT-PCR 30-1,470,000
  Versant™ HCV RNA 3.0 Siemens Health Care Diagnostics Semi-automated bDNA signal 
amplification
615-7,700,000
  Cobas TaqMan™ HCV Test Roche Molecular System Semi-automated real-time PCR 43-69,000,000
  Abbott RealTime™ HCV  Abbott Diagnostics Semi-automated RT-PCR 12-10,000,000
HCV, hepatitis C virus; RT-PCR, reverse transcription polymerase chain reaction; TMA, transcription-mediated amplification; bDNA, 
branched DNA.
Hepatitis C virus (HCV) causes various liver diseases including 
acute hepatitis, chronic hepatitis, health-holders, liver cirrhosis 
and hepatocellular carcinoma.
1 Acute hepatitis C progresses to 
chronic hepatitis from 75 to 85% and cirrhosis after 20-25 years 
later. In patients with HCV-positive cirrhosis, the annual 
incidence of hepatocellular carcinoma has been reported as 5% 
approximately.
1
The current standard antiviral treatment with peginterferon 
and ribavirin combination therapy is effective in about 50% of 
patients with chronic hepatitis C. It is assumed that achievement 
of sustained virological response (SVR) after the combination 
therapy, confirmed by means of commercial HCV RNA detection 
assays is regarded as a cure for chronic hepatitis C (Table 1). It is 
associated with histological improvement, reduced the risk of 
hepatocellular carcinoma and liver related mortality, and 
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Table 2. Reappearance rates of serum HCV RNA after achieving SVR 
Authors (published year) Patients No. Follow-up period (years) Detectable serum HCV RNA (%)
Marcellin et al
2 (1997) 80 4.0 (mean) 4
Reichard et al
14 (1999) 26 5.4 (mean) 8
McHutchison et al
3 (2002) 400 0.5 (maximum) 0.5
Veldt et al
5 (2004) 286 4.9 (maximum) 4.7
Khokhar
15 (2004) 57 3.0 (maximum) 8.8
Formann et al
6 (2006) 187 2.4 (median) 0
Desmond et al
7 (2006) 147 2.3 (mean) 0.7
Lindsay et al
8 (2008) 366 4.8 (mean) 1
Maylin et al
9 (2008) 344 3.3 (mean) 0
George et al
10 (2009) 147 5.4 (median) 0
Kim et al
11 (2009) 73 1.8 (maximum) 1.4
Swain et al
12 (2010) 1,343 3.9 (mean) 0.9
Trapero-Marugán et al
13 (2011) 153 6.1 (mean) 0
Lee et al
16 (2011) 68 1.8 (median) 7.4
Choi et al
4 (2011) 224 1.5 (median) 0
HCV, hepatitis C virus; SVR, sustained virological response.
For the respect of the durability of SVR, several studies have 
been reported. Marcellin et al
2 reported that an SVR after 
antiviral therapy was associated with long-term biochemical and 
virological responses as well as histologic improvement. 
Eighty-patients who had SVR after interferon-alpha monotherapy, 
mean follow-up of 4 years showed that 96% had undetectable 
serum HCV RNA. In a large-scale clinical trials, 7 (2%) among 
400 sustained virological responder had detectable hepatic HCV 
RNA during follow-up; 5 have been followed and 2 (0.5%) were 
reappearance of serum HCV RNA at 12 months after therapy.
3 
Many other reports including the study of Choi et al
4 confirmed 
that late relapse is rare after achievement of an SVR with 
completion of interferon without or with ribavirin therapy 
(Table 2).
5-13 On the other hand, earlier reports showed higher 
rate of late relapse.
14-16 These discrepancies may be resulted from 
use of HCV polymerase chain reaction (PCR) assays with 
varying degrees of sensitivity and a range of patient populations. 
As a result, the true durability of the response remains unclear, 
and the optimal follow-up for patients who have achieved an 
SVR is unknown.
Even then achievement of an SVR, there are many evidences 
that HCV can persist and replicate in peripheral blood 
mononuclear cells, hepatic tissue and other organs including 
kidney, heart, pancreas, intestine, adrenal gland, lymph node and 
gallbladder in spite of still undetectable serum HCV RNA.
3,17-21 
It is so called "occult HCV", which can be reservoir of 
reappearance HCV RNA in serum
3,21 and thus play a role in the 
persistence and reactivation of infection. Highly sensitive 
reverse transcription and nested PCR assays detected residual 
HCV RNA in case of occult HCV. However, these assays are not 
currently standard diagnostic procedures and whether these 
findings actually represent a replication-competent virus or have 
any clinical significance is not clear. The immunologic mechanism 
of HCV recurrence after SVR is also not well investigated. 
Quiroga et at
22 reported HCV-specific cellular immune responses 
are stronger in occult HCV infection than in chronic hepatitis C 
and it would be the cause of the rare incidence of late relapse.
For the factors affecting the durability of SVR, no distinct 
pattern of baseline characteristics could be identified. Several 
studies with small number of patients reported the transfusion, 
injection drug use or dose reduction as a risk factor. However, it 
was unknown whether these cases reflect relapse or re-infection 
because of the paucity of paired samples.
Although there is reappearance of serum HCV RNA in 
approximate 1% of patients with an SVR, individuals who have 
achieved an SVR should have a single additional follow-up HCV 
RNA measurement performed to ensure that the negative HCV 
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possibly due to faulty sample collection. If the second post- 
treatment HCV RNA measurement is negative, the SVR appears 
to be durable and a reliable sign of cure after antiviral therapy in 
chronic hepatitis C. However, it is recommended to follow up 
serum HCV RNA for a long time after an SVR for those 
individuals who show intermittent viral breakthrough during 
treatment or who may be considered at risk for reinfection or late 
relapse.
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